Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients’ well-being
Panagiota Flevari, MD*,*,
Efthimios G. Livanis, MD*,
George N. Theodorakis, MD*,
Elias Zarvalis, MD*,
Theoni Mesiskli, MD* and
Dimitrios T. h Kremastinos, MD*
* Second Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
View larger version (9K):
[in a new window]
|
Figure 1 Mean (±SE) number of syncopal episodes before and during therapy with propranolol, nadolol and placebo.
|
|
View larger version (9K):
[in a new window]
|
Figure 2 Mean (±SE) number of presyncopal episodes before and during therapy with propranolol, nadolol and placebo.
|
|
View larger version (13K):
[in a new window]
|
Figure 3 Patients’ self-assessed well-being before and during therapy with propranolol, nadolol and placebo.
|
|
|
